ProCE Banner Activity

Expert View on the Evolving Treatment Paradigm in Advanced NSCLC

Text Module
Review expert insights on the latest clinical data informing optimal management of patients with advanced NSCLC using targeted agents and immune checkpoint inhibitors.

Released: June 23, 2020

Expiration: June 22, 2021

No longer available for credit.

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Celgene

Loxo Oncology subsidiary of Eli Lilly

Partners

GRACE

ProCE Banner

Learning Objectives

  • Assess the appropriate molecular markers to guide clinical decisions for patients with advanced-stage NSCLC
  • Integrate into practice the available clinical evidence and expert recommendations after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Plan individualized treatment strategies for patients with advanced NSCLC positive for actionable genetic aberrations, or high PD-L1 expression, taking into consideration the available data and consensus expert recommendations
  • Plan treatment strategies using immune checkpoint inhibitors as first-line treatment options for patients with advanced NSCLC
  • Describe the role of combination approaches to optimize immune checkpoint inhibitor efficacy and reduce treatment resistance
  • Appropriately manage treatment-related adverse events associated with targeted and immune checkpoint inhibitor treatment options used in patients with NSCLC

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, BeyondSpring, Boehringer Ingelheim, Bristol-Myers Squibb, Inivata, and Takeda and funds for research support (to his institution) from Celgene, Merck, Novartis, OncoMed, and Roche.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Elaine S. DeMeyer, MSN, RN, AOCN

Editorial Contributor

Elaine DeMeyer, RN, MSN, AOCN, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.